{"type":"trials","record":{"id":86452,"source_id":"isrctn","external_id":"ISRCTN13894787","title":"Central Retinal Enrichment Supplementation Trials - enrichment of macular pigment in subjects with age-related macular degeneration (AMD)","brief_summary":"Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. The macula, the central part of the retina, is responsible for optimal spatial vision. There is a growing body of evidence that a lack of a dietary pigment at the macula, known as macular pigment, is associated with increased risk of AMD. Macular pigment contains the carotenoids lutein, zeaxanthin and meso-zeaxanthin (MZ). The typical western diet contains around 60 carotenoids, and 18 have been identified in human serum. However, only three carotenoids are found at the macula, indicating the unique biological selectivity for their uptake at this location. The function of macular pigment remains undetermined. It is likely that the accumulation of macular pigment has evolved because of its optical and antioxidant properties. For example, macular pigment limits retinal oxidative damage passively (through filtration of blue light) and actively (by quenching free radicals). Furthermore, its optical properties suggest a key role for macular pigment in enhancing visual performance and supporting optimal vision by reducing the effects of chromatic aberration and light scatter. Recent research…","overall_status":"Completed","phases":[],"study_type":"Interventional","sponsor":"European Research Council (ERC)","enrollment":150,"countries":["United Kingdom","Ireland"],"start_date":"2012-09-01","completion_date":"2016-05-31","last_update_date":"2017-10-23","source_url":"https://www.isrctn.com/ISRCTN13894787","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:45:34.939462+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN13894787; retrieved 2026-09-25","interventions":["Supplement"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Contrast sensitivity at 24 months of supplementation. The level of significance for changes will be set at 0.05","Current secondary outcome measures as of 28/01/2014: 1. Contrast sensitivity (measured using the Functional Vision Anal…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Age-related macular degeneration (AMD)","Current interventions as of 21/01/2014: Intervention 1: 10 mg lutein, 10 mg meso-zeaxanthin and 2 mg zeaxanthin plus 50…","results","protocol","Participant information sheet","Study website","Supplement"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn13894787","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2012-09-01 to 2016-05-31","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.587Z","intervention":["Supplement"],"participants":150,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Contrast sensitivity at 24 months of supplementation. The level of significance for changes will be set at 0.05","Current secondary outcome measures as of 28/01/2014: 1. Contrast sensitivity (measured using the Functional Vision Anal…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86452","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}